1.1 | Applicability across populations and settings | 0 |
1.2 | Compliance with jurisdictional law | 0 |
1.3 | Written policies and standard protocols | 0 |
1.4 | Care that is safe, high quality and tailored to the patient | 0 |
1.5 | Ethical basis and advocacy for the patient | 0 |
1.6 | Evidence over commercial influence | 0 |
10.1 | Record every part of the infusion care episode | 0 |
10.2 | Accurate dated and attributed entries | 0 |
10.3 | Legible timely and retrievable records | 0 |
10.4 | Records show continuity quality and safety | 0 |
10.5 | Documentation confidentiality and privacy policy | 0 |
10.A | Record consent and how the patient responded | 0 |
10.B | Standardised electronic record elements | 0 |
10.C | Insertion details recorded at the time | 0 |
10.D | Ongoing site and securement review | 0 |
10.E | Complications recorded with a standard tool | 0 |
10.F | Document how therapy was given | 0 |
10.G | Equipment and maintenance responsibility recorded | 0 |
10.H | Ongoing need for the device reviewed | 0 |
10.I | Removal documented in full | 0 |
10.J | Standard templates without limiting detail | 0 |
10.K | Use electronic records and standard terms | 0 |
10.L | Routine documentation audits | 0 |
10.M | Capture post treatment patient reported symptoms | 0 |
11.1 | Record and report adverse events | 0 |
11.2 | Safety science defined in policy | 0 |
11.A | Use standard tools to track adverse events | 0 |
11.B | Teach patients to spot complications | 0 |
11.C | Report to the right recipients in time | 0 |
11.D | Investigate serious events and act | 0 |
11.E.1 | Build a safety and reliability culture | 0 |
11.E.2 | Fix systems rather than blame people | 0 |
11.E.3 | Examine at risk behaviour and coach | 0 |
11.E.4 | Support teamwork and changes to how work is done | 0 |
11.E.5 | Simplify and standardise reporting | 0 |
11.E.6 | Use a systematic safety method | 0 |
11.E.7 | Monitor investigation recommendations | 0 |
11.E.8 | Patient safety raised on rounds | 0 |
11.F | A culture of openness and reporting | 0 |
11.G | Share learning and change practice | 0 |
11.H | Responsible disclosure of errors | 0 |
11.I | Include the patient in event review | 0 |
11.J | Match skills and staffing to reduce harm | 0 |
11.K | Support second victims of events | 0 |
12.1 | End users help judge products | 0 |
12.2 | End users keep product knowledge current | 0 |
12.3 | Check products before, during and after use | 0 |
12.4 | Remove and report expired or defective stock | 0 |
12.5 | Experts guide product substitution | 0 |
12.A | Judge products against set criteria | 0 |
12.B | Report product problems and monitor alerts | 0 |
13.1 | Controlled substance policies across medication pathway | 0 |
13.2 | Nonpunitive culture for diversion reporting | 0 |
13.3 | Competency for staff with substance access | 0 |
13.4 | Valid order for every controlled substance dose | 0 |
13.A | Run a diversion prevention programme | 0 |
13.B.1 | Opioid stewardship programme | 0 |
13.B.10 | Handle waste of unused controlled substances | 0 |
13.B.2 | Background checks before employment | 0 |
13.B.3 | Careful review of controlled substance orders | 0 |
13.B.4 | Electronic prescribing of controlled substances | 0 |
13.B.5 | Limit who can reach controlled substance storage | 0 |
13.B.6 | Chain of custody for controlled substances | 0 |
13.B.7 | Diversion education at orientation and after | 0 |
13.B.8 | Diversion content in health care curricula | 0 |
13.B.9 | Approved administration steps for controlled substances | 0 |
13.C.1 | Duty to report suspected diversion | 0 |
13.C.2 | Drug testing where the law permits | 0 |
13.C.3 | Resolving controlled substance discrepancies | 0 |
13.C.4 | Routine audits of the medication pathway | 0 |
13.C.5 | Removing an impaired worker from care | 0 |
13.C.6 | Reporting confirmed diversion externally | 0 |
13.C.7 | Managing outbreaks linked to diversion | 0 |
13.D.1 | Confidentiality and recovery support | 0 |
13.D.2 | Addiction treated as chronic illness | 0 |
13.D.3 | Watch practice after a worker returns from recovery | 0 |
14.1 | Reducing latex presence in the environment | 0 |
14.2 | Latex free protective equipment and supplies | 0 |
14.A | Identifying clinicians with latex allergy | 0 |
14.B | Identifying patients at risk of latex allergy | 0 |
14.C | Record and share a positive latex screen | 0 |
14.D | Tell latex sensitivity apart from true allergy | 0 |
14.E | Recognising latex exposure routes | 0 |
14.F | Use nonpowdered gloves without latex | 0 |
14.G | Minimising latex exposure for at risk people | 0 |
14.H | Allergist input to procurement decisions | 0 |
14.I | Teach patients and clinicians about anaphylaxis | 0 |
15.1 | Hazardous drug handling compliance | 0 |
15.2 | Safe handling across drug lifecycle | 0 |
15.3 | Hazardous waste container disposal | 0 |
15.A | Hazardous drug exposure protection | 0 |
15.B | Hazardous drug list upkeep | 0 |
15.C | Hazardous drug labeling | 0 |
15.D | Exposure risk points and controls | 0 |
15.E | Hierarchy of exposure controls | 0 |
15.F | PPE use and competency | 0 |
15.G | Reproductive and breastfeeding precautions | 0 |
15.H | Surface wipe sampling | 0 |
15.I | Medical surveillance program | 0 |
15.J | Hazardous drug training and competency | 0 |
15.K.1 | Closed-system transfer in compounding | 0 |
15.L.1 | Protective devices for administration | 0 |
15.L.2 | Aseptic preparation inside containment | 0 |
15.L.3 | Disposal of container with set | 0 |
15.L.4 | Back-priming outside containment | 0 |
15.L.5 | Pre-infusion connection inspection | 0 |
15.M | Spill preparedness and response | 0 |
15.N | Immediate exposure response | 0 |
15.O | Hazardous waste segregation | 0 |
15.P | Body fluid precautions after dose | 0 |
15.Q.1 | Home spill kit and cleaning | 0 |
15.Q.2 | Home laundry decontamination | 0 |
15.Q.3 | Home diaper and glove disposal | 0 |
16.1 | Regulated medical waste compliance | 0 |
16.2 | Needlestick risk in quality program | 0 |
16.3 | Sharps container requirements | 0 |
16.4 | Safety-engineered device availability | 0 |
16.A | Needlestick prevention during procedures | 0 |
16.B | Sharps and waste education | 0 |
16.C | Exposure reporting and follow-up | 0 |
16.D | Medical waste checklist | 0 |
16.E | Environmental impact of waste | 0 |
16.F | Packaging and ANTT choice | 0 |
16.G | Home infusion waste instruction | 0 |
16.H | Medical waste sorting | 0 |
17.1 | Routine hand hygiene | 0 |
17.A | Hand hygiene moments | 0 |
17.B | Alcohol-based hand rub use | 0 |
17.C | Soap and water indications | 0 |
17.D | Caution with chlorhexidine hand hygiene | 0 |
17.E | Hand hygiene supply access | 0 |
17.F | Fingernail care rules | 0 |
17.G | Jewelry removal for procedures | 0 |
17.H | Patient hand hygiene education | 0 |
17.I | Multimodal compliance strategy | 0 |
17.J | Hand hygiene monitoring and feedback | 0 |
17.K | Clinician product evaluation | 0 |
18.1 | Standard precautions for all patient care | 0 |
18.2 | PPE selection by exposure risk | 0 |
18.3 | Frequent cleaning of nearby surfaces | 0 |
18.4 | Prompt blood and body fluid spill cleanup | 0 |
18.5 | DME cleaning after every use | 0 |
18.A | Hand hygiene during standard precautions | 0 |
18.B | PPE access and timely removal | 0 |
18.C | Glove use and change rules | 0 |
18.D | Single-use gown or apron use | 0 |
18.E | Eye and face splash protection | 0 |
18.F | Universal PPE during high transmission | 0 |
18.G | Respiratory hygiene and cough etiquette | 0 |
18.H | DME disinfection with approved products | 0 |
18.I | Home care bag and equipment hygiene | 0 |
18.J | Multimodal standard precautions training | 0 |
19.1 | ANTT for all infusion procedures | 0 |
19.2 | ANTT education for clinicians and caregivers | 0 |
19.A | Standardize aseptic technique with ANTT | 0 |
19.B | ANTT as a core clinical competency | 0 |
19.C | Key-Part and Key-Site protection | 0 |
19.D.1 | Choosing ANTT approach through procedure risk assessment | 0 |
19.D.2 | Standard-ANTT for short, simple procedures | 0 |
19.D.3 | Surgical-ANTT for procedures that are complex | 0 |
19.E | Aseptic device disinfection and skin prep | 0 |
19.F | Sterile dressing and securement with ANTT | 0 |
19.G | Care setting decontamination before procedures | 0 |
19.H | Auditing and maintaining ANTT competency | 0 |
2.1 | What special patient populations need | 0 |
2.A.1 | Therapy considerations for neonatal and paediatric patients | 0 |
2.A.2 | Preterm infant skin and antiseptics | 0 |
2.A.3 | Child anatomy and access that is difficult | 0 |
2.A.4 | Psychosocial and cultural planning | 0 |
2.A.5 | Involving family and caregivers | 0 |
2.A.6 | Assent from school-aged and adolescent patients | 0 |
2.B.1 | Pregnancy physiology and dosing | 0 |
2.B.2 | Teaching about medication risk in pregnancy | 0 |
2.B.3 | Indication-only peripheral access in labour | 0 |
2.B.4 | PICC risk and hyperemesis nutrition | 0 |
2.C.1 | Ageing physiology and access that is harder | 0 |
2.C.2 | Assessing cognition, dexterity and social factors | 0 |
2.C.3 | Safe self-management at home | 0 |
2.C.4 | Involving family and surrogates | 0 |
2.C.5 | Polypharmacy and interaction risk | 0 |
2.C.6 | Dialysis access in elderly patients | 0 |
20.1 | Transmission-Based Precautions triggers | 0 |
20.2 | Contact Precautions for contact spread | 0 |
20.3 | Droplet Precautions for respiratory droplets | 0 |
20.4 | Airborne Precautions for airborne pathogens | 0 |
20.5 | Precautions in nonacute care settings | 0 |
20.6 | Precautions during crises of infectious disease | 0 |
20.A | PPE for transmission-based precautions | 0 |
20.B | Hand hygiene around PPE use | 0 |
20.C | Duration of Transmission-Based Precautions | 0 |
20.D | Contact Precautions with gown and gloves | 0 |
20.E | Droplet Precautions with mask and eye cover | 0 |
20.F | Airborne Precautions and the respirator program | 0 |
20.G | Enhanced barrier precautions in nursing homes | 0 |
20.H | Telling others about suspected infection on transfer | 0 |
20.I | Equipment that is dedicated and cleaned | 0 |
20.J | Crisis strategies for care in a pandemic | 0 |
21.1 | Vascular visualization to improve insertion success | 0 |
21.A | History review to judge insertion difficulty | 0 |
21.B | Ultrasound vessel assessment before cannulation | 0 |
21.C.1 | Visible light devices for superficial veins | 0 |
21.C.2 | Cold light only in visualization devices | 0 |
21.D.1 | Near infrared light for access that is difficult in children | 0 |
21.D.2 | Near infrared guidance in adult patients | 0 |
21.E | Catheter to vessel ratio below 45 percent | 0 |
21.F.1 | Ultrasound guidance for peripheral catheters in adults | 0 |
21.F.2 | Ultrasound guidance for peripheral catheters in children | 0 |
21.G | Real time ultrasound guidance for central device insertion | 0 |
21.H | Ultrasound guidance when puncturing arteries and placing catheters | 0 |
21.I | Probe cover and disinfection between uses | 0 |
21.J | Ultrasound training from novice to expert | 0 |
21.K | Assess and record visualization competence | 0 |
22.1 | Confirm tip position before infusion therapy | 0 |
22.2 | Record the original tip position and share it | 0 |
22.3 | Safest tip position at the cavoatrial junction | 0 |
22.A | Estimate catheter length before insertion | 0 |
22.B | Tip target by insertion route | 0 |
22.C | Avoid suboptimal tip positions | 0 |
22.D | No intracardiac tip in infants under one year | 0 |
22.E | Real time tip location during insertion | 0 |
22.F | Reassess tip position on suspicion of malposition | 0 |
22.G | Verify tip before starting infusion | 0 |
22.H | Accepting external catheters after transfer | 0 |
22.I | Document insertion time and tip location | 0 |
23.1 | Basis for choosing flow control devices | 0 |
23.2 | Anti free flow sets with electronic pumps | 0 |
23.A | Matching flow control to patient and therapy | 0 |
23.B | Monitor flow control devices during infusion | 0 |
23.C | Standardize pump types across the organization | 0 |
23.D | Reduce alarm and alert fatigue | 0 |
23.E | Flow control devices during care transitions | 0 |
23.F | Teach home users about flow control devices | 0 |
24.1 | Dedicated blood and fluid warming devices | 0 |
24.2 | Warming technique that limits hemolysis | 0 |
24.A | Competency for warming device operators | 0 |
24.B | Clinical indications for warming blood and fluids | 0 |
24.C | Approved warming equipment and safeguards | 0 |
24.D | Temperature limits and patient monitoring | 0 |
24.E | Warming contrast media safely | 0 |
25.1 | Collaborative infusion and access decisions | 0 |
25.2 | Device selection based on prescribed therapy | 0 |
25.3 | Least invasive device with fewest lumens | 0 |
25.4 | Site selection based on vessel health | 0 |
25.I.A | Assess infusate suitability for peripheral veins | 0 |
25.I.B | Discuss preferred peripheral site with patient | 0 |
25.I.C | Visualisation for midline vein selection | 0 |
25.I.D | Avoid peripheral sites at nerve risk | 0 |
25.I.E | Avoid compromised peripheral insertion areas | 0 |
25.I.F | Do not use trunk or breast veins | 0 |
25.I.G | Restrict lower extremity vein use | 0 |
25.I.H | Peripheral device not an infection prevention substitute | 0 |
25.I.I | Prefer existing port over new device | 0 |
25.II.A | Short peripheral site choice and removal | 0 |
25.II.B | Visualisation for difficult intravenous access | 0 |
25.II.C | No continuous irritant or vesicant via short catheter | 0 |
25.II.D | Restricted concentrations for peripheral nutrition | 0 |
25.II.E | Avoid deep and subcutaneous veins | 0 |
25.II.F | Smallest gauge catheter and monitoring | 0 |
25.III.A | Long peripheral catheter when vessel is unseen | 0 |
25.III.B | Long peripheral catheter vein and tip position | 0 |
25.IV.A | Assess infusates before midline use | 0 |
25.IV.B | Midline tip position distal to axillary fold | 0 |
25.IV.C | Consider anti biofilm midline catheter | 0 |
25.IV.D | Midline exclusions for vesicants and nutrition | 0 |
25.IV.E | Increase surveillance during irritant infusions | 0 |
25.IV.F | Avoid midline in thrombosis and renal risk | 0 |
25.V.A | Paediatric peripheral catheter criteria and sites | 0 |
25.VI.A | Avoid venipuncture with lymphedema risk | 0 |
25.VI.B | Vein preservation with renal dysfunction | 0 |
25.VI.C | Avoid paralysed or hemiparetic limb | 0 |
25.VII.A.1 | Direct route versus skin tunnel | 0 |
25.VII.A.2 | Evidence based central access indications | 0 |
25.VII.A.3 | Central access after failed peripheral attempts | 0 |
25.VII.A.4 | Know the pressure limits for power injection | 0 |
25.VII.A.5 | Team choice of central device type | 0 |
25.VII.B.1 | PICC vein selection and catheter-to-vessel ratio | 0 |
25.VII.B.2 | Avoid tender, wounded, or damaged veins | 0 |
25.VII.C.1 | Ultrasound for non tunnelled central insertion | 0 |
25.VII.C.2 | Risk-based site selection for central catheters | 0 |
25.VII.D.1 | Atypical tunnelled noncuffed central catheter | 0 |
25.VII.D.2 | Tunnelled femoral PICC to the middle of the thigh | 0 |
25.VII.E.1 | Collaborative site selection for tunnelled devices | 0 |
25.VII.E.2 | Prefer internal jugular over other sites | 0 |
25.VII.E.3 | Ultrasound assessment of chest veins | 0 |
25.VII.E.4 | Tunnelled device for long term continuous therapy | 0 |
25.VII.E.5 | Port for intermittent access needs | 0 |
25.VII.E.6 | Nonconventional access for exhausted veins | 0 |
25.VIII.A | Arterial catheter indications | 0 |
25.VIII.B | Smallest gauge for radial arterial access | 0 |
25.VIII.C | Ultrasound for arterial catheter placement | 0 |
25.VIII.D | Checking hand circulation before radial puncture | 0 |
25.VIII.E | Radial artery as first choice in adults | 0 |
25.VIII.F | Sites for arterial access in children | 0 |
26.1 | Skin antisepsis before each port access | 0 |
26.2 | Noncoring needle use for port access | 0 |
26.3 | Sterile dressing over an accessed port | 0 |
26.A | Pain preferences during port access | 0 |
26.B | Use the existing port before new access | 0 |
26.C | Aseptic technique for port access | 0 |
26.D | Smallest noncoring needle for the therapy | 0 |
26.E | Port flushing and locking to keep it patent | 0 |
26.F | Dressing and securement of the accessed port needle | 0 |
26.G | Checking a port for power injection | 0 |
26.H | Annual imaging check of port position | 0 |
26.I | Education for patients and caregivers with ports | 0 |
27.1 | Choosing a dialysis access device jointly | 0 |
27.2 | Protect the fistula or graft arm | 0 |
27.3 | Restricted access to dialysis catheter lumens | 0 |
27.A | Protecting vessels in people on dialysis | 0 |
27.B | Aseptic care of dialysis access sites | 0 |
27.C | Hub care and catheter lumen disinfection | 0 |
27.D | Locking solutions for hemodialysis catheters | 0 |
27.E | Surveillance of dialysis adverse events | 0 |
27.F | Patient engagement and dialysis education | 0 |
28.1 | Daily review of umbilical catheter need | 0 |
28.A | Organisational guidance on umbilical catheters | 0 |
28.B | Skin antisepsis for umbilical catheter insertion | 0 |
28.C.1 | Tip placement for umbilical arterial catheters | 0 |
28.C.2 | Tip placement for umbilical venous catheters | 0 |
28.D | Estimating and confirming catheter length | 0 |
28.E | Imaging confirmation of umbilical catheter tip | 0 |
28.F | Securement of umbilical catheters | 0 |
28.G | No antibiotic ointment on umbilical sites | 0 |
28.H | Watching for umbilical catheter complications | 0 |
28.I | Care bundle for umbilical catheter infection | 0 |
28.J | Prompt removal of umbilical catheters | 0 |
29.1 | Vascular access choice for therapeutic apheresis | 0 |
29.A | Criteria for selecting an apheresis access device | 0 |
29.B | Peripheral or central access for apheresis | 0 |
29.C | Dialysis-capable catheters for apheresis | 0 |
29.D | Long-term apheresis ports | 0 |
29.E | Avoid fistulas and grafts for long-term apheresis | 0 |
3.1 | Qualified and competent clinicians | 0 |
3.2 | Defined roles and accountability | 0 |
3.3 | Team collaboration for safe therapy | 0 |
3.4 | Rules for delegating infusion and access work | 0 |
3.A | Licensure and defined scope | 0 |
3.B | How scope of practice is defined | 0 |
3.C | Using a scope-of-practice decision framework | 0 |
3.D | Team roles and shared scope boundaries | 0 |
3.E | The five rights of delegation | 0 |
3.F | Nursing roles in infusion therapy | 0 |
3.G | Unlicensed assistive personnel limits | 0 |
3.H | Other disciplines and jurisdictional variation | 0 |
30.1 | Right to pain management | 0 |
30.2 | Strategies to reduce needle-related pain | 0 |
30.A | Realistic pain expectations and shared decisions | 0 |
30.B | First-attempt success as pain reduction | 0 |
30.C | Barriers to using pain relief strategies | 0 |
30.D.1 | Pain assessment in infants | 0 |
30.D.2 | Pain assessment in toddlers | 0 |
30.D.3 | Pain assessment in preschool and school-age children | 0 |
30.D.4 | Pain assessment in children with intellectual disability | 0 |
30.D.5 | Pain assessment in adults | 0 |
30.E.1 | Parent involvement in neonatal pain management | 0 |
30.E.2 | Nonpharmacologic relief for neonatal pain | 0 |
30.E.3 | Avoid anesthetic cream in neonates | 0 |
30.E.4 | Culturally based comfort strategies for infants | 0 |
30.E.5 | Massage therapy for neonatal procedural pain | 0 |
30.F.1 | Parents managing a child's procedural pain | 0 |
30.F.2 | Distraction techniques for children | 0 |
30.G | Ice before venipuncture in children | 0 |
30.H.1 | Topical anesthetics compared for children | 0 |
30.H.2 | Topical versus needleless lidocaine for child insertions | 0 |
30.H.3 | Vapocoolant spray for children | 0 |
30.I.1 | Needle phobia in adult patients | 0 |
30.I.2 | Nonpharmacologic pain relief for adults | 0 |
30.I.3 | Pharmacologic pain relief for adults | 0 |
31.1 | Skin antisepsis before device insertion | 0 |
31.2 | Clean site before antiseptic application | 0 |
31.A | Hair removal at the insertion site | 0 |
31.B | Antiseptic allergy history check | 0 |
31.C | Choice of skin antiseptic solution | 0 |
31.D | Single-use applicator and full drying | 0 |
32.1 | Single sterile device per attempt | 0 |
32.2 | Device used within manufacturer instructions | 0 |
32.3 | CVAD tip position verified before use | 0 |
32.4 | Patient education before device insertion | 0 |
32.I.A | Local PIVC insertion bundle | 0 |
32.I.B | Early referral for difficult access | 0 |
32.I.C | Pain relief for insertion | 0 |
32.I.D | Visualisation for vein assessment | 0 |
32.I.E.1 | Ultrasound guidance for long PIVC | 0 |
32.I.E.2 | Vessel depth for long PIVC | 0 |
32.I.E.3 | Long PIVC in monitored settings | 0 |
32.I.F | Aids to distend peripheral veins | 0 |
32.I.G | Aseptic technique for PIVC insertion | 0 |
32.I.H | Limit PIVC attempts per clinician | 0 |
32.I.I | Midline catheter length and tip | 0 |
32.I.J | Immediate PIVC removal triggers | 0 |
32.II.A | Central line bundle at CVAD insertion | 0 |
32.II.B | Ultrasound guidance when inserting a CVAD | 0 |
32.II.C | Right-sided PICC and vein ratio | 0 |
32.II.D | Manage CVAD insertion complications | 0 |
32.II.E | CVAD tip at cavoatrial junction | 0 |
32.II.F | Complex CVAD insertion with cardiac devices | 0 |
32.III.A | Ultrasound for arterial access | 0 |
32.III.B | Dynamic needle tip positioning for arteries | 0 |
32.III.C | Attire and drape for arterial catheter | 0 |
32.III.D | Surgical ANTT for central arterial access | 0 |